Kevin Brewer
Analyst · B. Riley. Craig
Thank you, Mary, and good morning. Axcelis delivered exceptional second quarter financial results, beating company guidance and consensus estimates across the board. Favorable mix with higher gross margin and solid execution drove these positive results. Supply chain disruption was significant in Q2 caused by pandemic-related shutdowns, nagging chip shortages and capacity. Throughout the quarter, our purchasing and engineering teams work closely with suppliers to implement both strategic and tactical measures to address these issues. Our manufacturing team addressed challenges created by material availability, while sales and service teams were sit with customers to support fab ramp plans and high utilization rates. As Mary mentioned, 2022 is on track to be another great year for Axcelis. We now expect full year revenue to be greater than $875 million. Visibility remains good and customer demand remains strong. Like others in the industry, we are dealing with similar supply chain disruption and higher costs. We try to include these anticipated challenges into our Q3 and full year guidance, but the situation changes almost daily. The only content right now is that the industry is supply chain constrained. We have continued to make improvements in our manufacturing capability in both Beverly and South Korea. In the second quarter, we significantly ramped production at the new Axcelis Asia operation center in South Korea and began additional projects to increase manufacturing capacity in Beverly. These efforts will enable us to support greater than $1 billion in revenue. Moving to our second quarter financial results. Q2 revenue finished at $221.2 million and above our guidance compared to $203.6 million in Q1. Q2 systems revenue was $165.4 million compared to $151.8 million in Q1. Q2 CS&I revenue finished at $55.8 million compared to $51.8 million in Q1. CS&I posted very strong margins in the quarter due to mix and some lower costs. We expect Q3 CS&I revenue to be around $55 million and recommend modeling the remainder of 2022 at $55 million per quarter. Q2 sales of our top 10 customers accounted for 66.3% of our total sales compared to 69.8% in Q1. Two customers were at 10% or above in Q2, the same as in Q1. Q2 system bookings were $432.8 million compared to $315.5 million in Q1, with a Q2 book-to-bill ratio of 2.56 versus 2.0 in Q1. Backlog in Q2, including deferred revenue, finished at $869.5 million, a new record, compared to $625 million in Q1. Multiple customers are planning new fabs and expansions for 2023 and 2024, which is driving bookings out beyond 1 year. Q2 combined SG&A and R&D spending was $45 million or 20.4% of revenue compared to $40.8 million or 20.1% in Q1. SG&A in the quarter was $26.3 million, with R&D to $18.7 million. In Q3, we expect SG&A and R&D spending to be approximately 21% of revenue. For the full year, I recommend modeling SG&A and R&D spending at approximately 21% of revenue. Gross margin was 44.8% and well above our guidance. Gross margin in the quarter was higher than guidance due to a more favorable mix of systems and higher-than-normal CS&I margins. We're guiding Q3 gross margin of approximately 42%, driven by the expected shipment of a less favorable systems mix compared to Q2 and the increased impact of supply chain-related costs. Full year 2022 gross margin is expected to be approximately 42.5%, which includes the impact of supply chain and logistics headwind. We believe we are at the trough and should begin recovering during 2023. We are continuously evaluating ways to help offset increased costs, but customer satisfaction remains our top priority. Outside of the higher costs I mentioned, we continue to make progress on core gross margin initiatives. Our $1 billion model reflects continued gross margin expansion driven by higher revenue from CS&I and Purion product extensions, incremental supply chain volume and value engineering, planned labor and quality improvements and a return to a more typical supply chain and logistics environment. Operating profit in Q2 finished at $54.1 million compared to $48.9 million in Q1. We're guiding Q3 operating profit between $44.5 million and $47.5 million. Q2 net income was $44.2 million or $1.32 per share compared to $41.6 million or $1.22 per share in Q1. We're guiding Q3 earnings per share between $1.10 and $1.15. As noted earlier, our Q3 guidance reflects the anticipated impact on our business from supplier and pandemic-related issues but remains an evolving situation. Q2 receivables were $146.1 million compared to $119 million in Q1, driven by the timing of shipments. Q2 inventory ended at $213.1 million compared to $203.8 million in Q1. Q2 inventory turns, excluding evaluation tools, finished at 2.6% compared to 2.5% in Q1. Future accounts payable were $49.4 million compared to $50.8 million in Q1. Q2 cash finished at $288 million compared to $298 million in Q1, driven by an increase in working capital. In the quarter, we generated $3.5 million of cash from operations and settled share repurchases of approximately $12.5 million. We have returned over $107 million of cash to our shareholders since beginning our stock repurchase programs. This is an exciting time for Axcelis with significant growth in the ion implant TAM, solid customer demand for our products and long-term growth prospects in the power device market. We are executing at a very high level, despite a challenging environment. And once again, I want to thank the entire team for continuing to perform at this level. I also want to thank our supply chain partners for their hard work supporting Axcelis and our customers during these unusual times. We have both projects underway, focused on stabilizing our supply chain and adding manufacturing capacity. As a result, we believe that Axcelis will emerge from this period with a stronger and much more resilient business. Thank you. I'll now turn the call back to Mary for closing comments.